Bli medlem
Bli medlem

Du är här


Nordic Nanovector: Title: Extraordinary General Meeting held in Nordic Nanovector AS

Date: 27.06.2014        Press Release no: 18/2014

Reference is made to the notice of Extraordinary General Meeting
distributed to the shareholders of Nordic Nanovector AS on 19 June

In accordance with the proposals set out in the notice, the
Extraordinary General Meeting has today resolved to issue 10 million
new shares in the Private Placement at a price of NOK 25 raising
gross proceeds of NOK 250 million. Furthermore, it was resolved to
conduct a subsequent share issue of up to 2 million new shares at a
price of NOK 25, raising gross proceeds of up to NOK 50 million.

The subsequent share issue will be directed towards the shareholders
of the Company as of 27 June 2014 except for (i) shareholders
participating in the Private Placement, and (ii) shareholders in
jurisdictions other than Norway and where an offer to participate in
the share issue is not allowed or would require approval or
registration of a prospectus or similar measures.

If not all subscription rights are used by the eligible holders, then
the remaining shares may be subscribed to by the shareholders of the
Company as of 27 June 2014. The allotment of these remaining shares
shall take place on the basis of shareholding as of that date, but so
that shares allotted to the shareholder in the Private Placement or
pursuant to subscription rights in the subsequent share issue shall
be deemed to be allotted shares.

The Company will prepare a prospectus in connection with the
subsequent share issue. The subscription period in the subsequent
share issue will not commence until the prospectus is approved by the
Financial Supervisory Authority of Norway (the "NFSA") and the
prospectus has been published.

The Company expects that the prospectus will be approved by the NFSA
in late August 2014. Eligible holders will receive the prospectus and
a subscription form by mail when the prospectus has been approved.

The Extraordinary General Meeting also resolved the other matters on
the agenda in accordance with the proposals of the Board of
Directors, as further set out in the attached minutes of the
Extraordinary General Meeting.

ABG Sundal Collier and DNB Markets have acted as managers in the
private placement and will act as managers in the subsequent share

Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07

Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07

About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009.
The company is based in Norway and has offices and laboratories in
Oslo. The company is developing novel innovative anticancer
radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other
hematological malignancies.

About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a
radionuclide conjugated to a tumor seeking carrier/antibody, which
can be used for irradiation of malignant metastasized tumors with
minimal damage to nearby healthy normal tissue. This technology aims
to prolong and improve the quality of life of people who suffer from
non-Hodgkin Lymphoma (NHL).

This announcement is not and does not form a part of any offer for
sale of securities.

Copies of this announcement are not being made and may not be
distributed or sent into the United States, Australia, Canada, Japan
or any other jurisdiction in which such distribution would be
unlawful or would require registration or other measures.

The securities referred to in this announcement have not been and will
not be registered under the U.S. Securities Act of 1933, as amended
(the "Securities Act"), and accordingly may not be offered or sold in
the United States absent registration or an exemption from the
registration requirements of the Securities Act and in accordance
with applicable U.S. state securities laws. The Company does not
intend to register any part of the offering in the United States or
to conduct a public offering of securities in the United States. Any
offering of the securities referred to in this announcement will be
made by means of a prospectus.

This announcement is not a prospectus for the purposes of Directive
2003/71/EC (together with any applicable implementing measures in any
Member State, the "Prospectus Directive"). Investors should not
subscribe for any securities referred to in this announcement except
on the basis of information contained in the aforementioned
prospectus. In any EEA Member State other than Norway that has
implemented the Prospectus Directive, this communication is only
addressed to and is only directed at qualified investors in that
Member State within the meaning of the Prospectus Directive, i.e.,
only to investors who can receive the offer without an approved
prospectus in such EEA Member State.

This communication is only being distributed to and is only directed
at persons in the United Kingdom that are (i) investment
professionals falling within Article 19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005, as amended
(the "Order") or (ii) high net worth entities, and other persons to
whom this announcement may lawfully be communicated, falling within
Article 49(2)(a) to (d) of the Order (all such persons together being
referred to as "relevant persons"). This communication must not be
acted on or relied on by persons who are not relevant persons. Any
investment or investment activity to which this communication relates
is available only to relevant persons and will be engaged in only
with relevant persons. Persons distributing this communication must
satisfy themselves that it is lawful to do so.

The information, opinions and forward-looking statements contained in
this announcement speak only as at its date, and are subject to
change without notice.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.